NDA 208745 · Salix
Trulance
Plecanatide · Oral · Guanylate Cyclase-C Agonist
NovelLast checked: Nov 20, 2026Latest source record: Apr 13, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Jan 19, 2017
Approved uses
2
Original approval plus efficacy supplements
Registered trials
14
8 Phase 3, 0 recruiting
FAERS reports
2,075
758 serious, 77 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS TRULANCE is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile mice, administration of a single oral dose of plecanatide caused deaths due to dehydration [see Contraindications (4) , Use in Specific Populations (8.4) ] . Avoid use of TRULANCE in patients 6 years to less than 18 years of age [see Warnings and Precautions (5.1) , Use in Specific Populations (8.4) ] . The safety and effectiveness of TRULANCE have not been established in patients less than 18 years of age [see Use in Specific Populations (8.4) ] . WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS See full prescribing information for complete boxed warning. TRULANCE is contraindicated in patients less than 6 years of age; in young juvenile mice, plecanatide caused death due to dehydration. ( 4 , 8.4 ) Avoid use of...
What it is approved for
From the label in effect Apr 4, 2024.
TRULANCE is indicated in adults for the treatment of: chronic idiopathic constipation (CIC). irritable bowel syndrome with constipation (IBS-C). TRULANCE is a guanylate cyclase-C agonist indicated in adults for treatment of: chronic idiopathic constipation (CIC). ( 1 ) irritable bowel syndrome with constipation (IBS-C). ( 1 )
Mechanism: Plecanatide is a structural analog of human uroguanylin, and similarly to uroguanylin, plecanatide functions as a guanylate cyclase-C (GC-C) agonist. Both plecanatide and its active metabolite bind to GC-C and act locally on the luminal surface of the intestinal epithelium. Activation of GC-C results in an increase in both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP). Elevation of extracellular cGMP has been associated with a decrease in the activity of pain-sensing nerves in animal models of visceral pain. Elevation of intracellular cGMP stimulates...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 24, 2018 Supplement 1 · Efficacy LabelLetter
- Jan 19, 2017 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- TRULANCE · PLECANATIDE 3MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Plecanatide" as an intervention, any sponsor and status, largest first.
- Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)Pivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT01919697 · 2,370 participants · Start Aug 2013 · Primary completion Jan 2016
Drug: Plecanatide · For: Chronic Idiopathic Constipation
Sites: Birmingham, Alabama; Dothan, Alabama; Gulf Shores, Alabama · 220 sites in all
- Long Term Safety Study of PlecanatidePivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT02706483 · 2,272 participants · Start Jan 2016 · Primary completion May 2017
Drug: Plecanatide · For: Irritable Bowel Syndrome
Sites: Athens, Alabama; Birmingham, Alabama; Dothan, Alabama · 204 sites in all
- 12-Week Study of Plecanatide for CIC (The National CIC3 Study)Pivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT02122471 · 1,410 participants · Start Apr 2014 · Primary completion May 2015
Drug: Plecanatide; Placebo · For: Chronic Idiopathic Constipation
Sites: Anniston, Alabama; Huntsville, Alabama; Chandler, Arizona · 167 sites in all
- 12-Week Study of Plecanatide for CIC (The CIC3 Study)Pivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT01982240 · 1,394 participants · Start Nov 2013 · Primary completion Apr 2015
Drug: Plecanatide; Placebo and 1 more · For: Chronic Idiopathic Constipation
Sites: Birmingham, Alabama; Dothan, Alabama; Gulf Shores, Alabama · 189 sites in all
- Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)Pivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT02493452 · 1,135 participants · Start Jun 2015 · Primary completion Nov 2016
Drug: Plecanatide; Placebo · For: Irritable Bowel Syndrome Characterized by Constipation
Sites: Birmingham, Alabama; Guntersville, Alabama; Huntsville, Alabama · 191 sites in all
- The Plecanatide Irritable Bowel Syndrome With Constipation Safety and Efficacy Study (IBS-C)Pivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT02387359 · 1,054 participants · Start Dec 2014 · Primary completion Dec 2016
Drug: Plecanatide; Placebo · For: Irritable Bowel Syndrome Characterized by Constipation
Sites: Athens, Alabama; Birmingham, Alabama; Dothan, Alabama · 155 sites in all
- The Plecanatide Chronic Idiopathic Constipation (CIC) StudyPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT01429987 · 951 participants · Start Oct 2011 · Primary completion Dec 2012
Drug: plecanatide · For: Chronic Idiopathic Constipation
Sites: Mobile, Alabama; Chandler, Arizona; Tucson, Arizona · 121 sites in all
- Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional ConstipationPivotal-lookingCompleted
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.Industry
NCT05151328 · 648 participants · Start Mar 18, 2022 · Primary completion Oct 12, 2023
Drug: Plecanatide · For: Functional Constipation
Sites: Wuhan, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea405
- nausea181
- drug ineffective175
- constipation174
- abdominal distension120
- fatigue119
- abdominal pain113
- abdominal pain upper108
- headache108
- dizziness102
- pain102
- product use in unapproved indication77
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 4 |
| 2017 | 150 |
| 2018 | 205 |
| 2019 | 217 |
| 2020 | 262 |
| 2021 | 224 |
| 2022 | 201 |
| 2023 | 199 |
| 2024 | 187 |
| 2025 | 196 |
| 2026 | 230 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Trulance (Plecanatide)
2024 spending
$123M
Beneficiaries
44,622
155,096 claims
Per beneficiary
$2,762
$18.11 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $7,814,398 |
| 2021 | $65,636,493 |
| 2022 | $87,600,523 |
| 2023 | $119,256,824 |
| 2024 | $123,236,395 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis.
Luthra P, Camilleri M, Burr NE, et al. · Lancet Gastroenterol Hepatol 2019 · Research Support, N.I.H., Extramural, Systematic Review
- The Effectiveness of Plecanatide for Treating Constipation and Bloating in Patients Aged 18 to 40ߙYears With Irritable Bowel Syndrome: Utilization of a New Composite Trisymptom Endpoint.
Brenner DM, Shin AS, Laitman AP, et al. · J Gastroenterol Hepatol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and safety of pharmacological therapies for functional constipation in children: a systematic review and meta-analysis.
de Geus A, Gordon M, Sinopoulou V, et al. · Lancet Child Adolesc Health 2025 · Systematic Review, Meta-Analysis
- Influence of Demographic Factors on Clinical Outcomes in Adults With Chronic Idiopathic Constipation Treated With Plecanatide.
Rao SSC, Laitman AP, Miner PB · Clin Transl Gastroenterol 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III Trials.
Moshiree B, Schoenfeld P, Franklin H, et al. · Clin Ther 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Bai T, Xu Z, Zhen Y, et al. · Drugs 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Salix
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.